In an interview with Biostock, CEO Anders Weilandt provides more details about Chordate Medical’s agreement to install Ozilia Migraine at a private specialist clinic in Germany for commercial use, and the company’s new market expert in the United Arab Emirates for the introduction of migraine and rhinitis treatment.
“It is very satisfying to achieve a breakthrough in Germany as it is one of the markets we are focusing on. This will undoubtedly make it easier to continue converting prospects into orders in Germany. our main focus is to build proof-of-concept (PoC) in the market, i.e. to show that we can gain customers and that they build up a volume of repeat patients. That is our strategic goal. In that process, revenues will also increase, which we are working towards, but the real goal is PoC.”